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3Abstract
The reaction of 5,15-diHpETE with human 5-lipoxygenase (LOX), human platelet 
12-LOX and human reticulocyte 15-LOX-1 was investigated to determine the reactivity 
and relative rates of producing lipoxins (LXs). 5-LOX does not react with 5,15-diHpETE,
although it can produce LXA4 when 15-HpETE is the substrate. In contrast, both 12-
LOX and 15-LOX-1 react with 5,15-diHpETE, forming specifically LXB4. For 12-LOX and 
5,15-diHpETE, the kinetic parameters are kcat = 0.17 s-1 and kcat/KM = 0.011 μM-1s-1 
(106-fold and 1600-fold lower than for 12-LOX oxygenation of AA, respectively). On the
other hand, for 15-LOX-1 the equivalent parameters are kcat = 4.6 s-1 and kcat/KM = 0.21
μM-1s-1 (3-fold higher and similar to that for 12-HpETE formation by 15-LOX-1 from 
AA, respectively). This contrasts with the complete lack of reaction of 15-LOX-2 with 
5,15-diHpETE (Biochemistry 55, 2832-2840, 2016). Our data indicate that 12-LOX is 
markedly inferior to 15-LOX-1 in catalyzing the production of LXB4 from 5,15-diHpETE. 
Platelet aggregation was inhibited by the addition of 5,15-diHpETE, with an IC50 of 1.3
μM, however, LXB4 did not significantly inhibit collagen-mediated platelet activation up
to 10 μM. In summary, LXB4 is the primary product of 12-LOX and 15-LOX-1 catalysis if
5,15-diHpETE is the substrate, with 15-LOX-1 being 20-fold more efficient than 12-LOX.
LXA4 is the primary product with 5-LOX, but only if 15-HpETE is the substrate. 
Approximately equal proportions of LXA4 and LXB4 are produced by 12-LOX, but only if 
LTA4 is the substrate, as described previously (Biochimica et Biophysica Acta 1133, 
223-234, 1992).
4Introduction: 
Lipoxins (LXs) were discovered in 19841,  2 and are a class of  specialized pro-
resolving mediators (SPMs) derived from arachidonic acid (AA), which are involved in
inflammation  resolution.  The  first  two  LXs  discovered  were  lipoxinA4 (LXA4)  and
lipoxinB4 (LXB4), with the epi-lipoxins, 15-epi-LXA4 and 15-epi-LXB4, being discovered
later.3 The  initial  step  of  acute  inflammation  is  to  recruit  macrophages  with  the
generation  of  leukotrienes  (LTs)  and  hydroxyeicosatetraenoic  acids  (HETEs).
Eventually, SPMs, such as LXs, are generated via transcellular pathways to reverse the
inflammatory response and initiate cellular repair.4 Researchers have investigated the
biosynthetic  pathway  for  the  production  of  LXs  and  the  generally  accepted
biosynthesis of LXs requires two distinct enzymatic reactions with AA. The first step is
the oxygenation of AA to form a hydroperoxide, which is then converted to an epoxide.
This  can  be  accomplished  by  either  5-LOX  or  15-LOX,  generating  either  the  5,6-
epoxide or the 14,15-epoxide,  respectively.  The second step is oxygenation at the
other end of the molecule from the epoxide, adding a hydroperoxide moiety. There is
then  a  subsequent  hydrolysis  of  the  epoxide  and reduction  of  the  hydroperoxide,
creating  either  the  5,6,15-trihydroxy-  or  the  5,14,15-trihydroxy-eicosatetraenoate,
depending on the initiating LOX isozyme (Figure 1).5, 6 The specific pathway depends
on  the  cell  type  involved,  either  with  one  cell  type  that  has  both  LOXs,  or  a
transcellular  biosynthetic  pathway,  which  involves  the  transfer  of  an  intermediate
between  two  cell  types.  Another  biosynthetic  pathway  for  LXs  involves  5-LOX  in
neutrophils and 12-LOX in platelets. The hypothesis is that 5-LOX generates LTA4 in
the neutrophil, which is then transferred to the platelet, where 12-LOX subsequently
abstracts a hydrogen atom from C13 of LTA4, with oxygen attacking C15. The epoxide
ring is subsequently opened by a hydrolase, generating a delocalized cation, which is
5attacked by water, generating either LXA4 with a C6 attack or LXB4 with a C14 attack
(Figure 1).7, 8
Another pathway to making LXs, involves 5,15-diHpETE as an intermediate. A
hydrogen  atom is  abstracted  from C10  of  5,15-diHpETE,  generating  a  delocalized
radical, which can convert either the C5 hydroperoxide or the C15 hydroperoxide to an
epoxide (5,6- or 14,15-epoxide). Subsequent hydrolysis of the expoxide and reduction
of the hydroperoxide generates either the 5,6,15-trihydroxy- or the 5,14,15-trihydroxy-
eicosatetraenoates. Like the cation intermediate discussed above, both LXA4 and LXB4
can be generated in  this  manner  since  the  resulting  radical  is  delocalized  over  9
carbons due to the full conjugation of the tetraene system (Figure 1).9 The reactivity of
this  chemical  step  is  enhanced  by  the  fact  that  5,15-diHpETE  is  an  “activated”
 
Figure 1: Biosynthetic pathways for LX production. The carbon whose hydrogen atom is abstracted is 
listed next to the LOX isozyme, such as C7, C10 or C13. For the conversion of 5,15-DiHpETE to the two lipoxins, 
6intermediate.  The energy required  to  abstract  the  C10 hydrogen atom from 5,15-
diHpETE  is  markedly  lower  than  the  hydrogen  atom  from  AA  or  5-
hydroperoxyeicosatetraenoic  acid  (5-HpETE),  due  to  the  greater  conjugation  of  its
intermediate,  9-carbons  for  5,15-diHpETE  versus  5-carbons  for  AA.9 Therefore,  the
ease  of  hydrogen  atom abstraction  from 5,15-diHpETE  could  enhance  the  rate  of
either LXA4 or LXB4 biosynthesis.
This last biosynthetic pathway is supported by fact that the LX intermediate,
5,15-diHpETE,  is  observed  in  a  variety  of  biological  samples.  One  of  the  earliest
observations of 5,15-diHpETE was in activated porcine leukocytes, when either AA or
15-HpETE were added as precursors.10 5,15-diHpETE was also observed with isolated
porcine 5-LOX, which reacted with 15-HpETE, at a 30% rate of that with AA.11 5,15-
diHpETE could then be further modified to LXB4 with purified rabbit reticulocyte 15-
LOX-1 (r15-LOX-1), presumably due to an epoxide intermediate.12 r15-LOX-1 could also
convert 15-HETE to LXB4, which was due to double oxygenation at C5 and C15, as
evidenced by labeled O2 being found on both carbons.12, 13 Porcine leukocyte 12-LOX
also converts 5,15-diHpETE to LXB4,  which was deduced by the observation of four
isomers of LXB4, due to the non-enzymatic hydrolysis of 5-OH,14,15-LTA4.14 LXB4 was
also  produced  by incubation  of  15-HpETE with  human leukocytes,  with  labeled O2
incorporating  into  only  C5,  and  not  C14,  indicating  the  presence  of  a  hydrolyzed
14,15-epoxide.15 5,15-diHpETE can also be generated by the addition of AA to human
eosinophils, where both 15-LOX-1 and 5-LOX are present.16
Previously, we have shown that human epithelial 15-LOX-2 does not react with
5,15-diHpETE and thus it is not implicated in producing LXs though this intermediate.9
In the present study, we expand this investigation into the biosynthetic pathway of LXs
generation from 5,15-diHpETE by comparing the relative activities of human 5-LOX,
7human  platelet  12-LOX  and  human  reticulocyte  15-LOX-1.  These  results  will  help
establish a better understanding of the relative roles of these three LOX isozyme in
the biosynthesis of LXs from 5,15-diHpETE. 
Methods
Chemicals. The lipid mass spectrometry standards, 5S,15S-dihydroxy-6E,8Z,11Z,13E-
eicosatetraenoic  acid  (5,15-diHETE),  5S,6R,15S-trihydroxy-7E,9E,11Z,13E-
eicosatetraenoic  acid  (LipoxinA4 (LXA4)),  and  5S,14R,15S-trihydroxy-6E,8Z,10E,12E-
eicosatetraenoic  acid  (LipoxinB4 (LXB4)),  were  purchased  from  Cayman  Chemical.
Arachidonic acid (AA) was purchased from Nu Chek Prep, Inc. and used to synthesize
5S-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic  acid  (5-HETE),  13S-hydrperoxy-9Z,11E-
octadecadienoic  acid  (13-HPODE),  5S,15S-hydroxy-6E,8Z,11Z,13E-eicosatetraenoic
acid  (5,15-diHETE),  5S-hydro-15S-peroxy-6E,8Z,11Z,13E-eicosatetraenoic  acid
(5OH,15-HpETE),  and  5S,15S-dihydroperoxy-6E,8Z,11Z,13E-eicosatetraenoic  acid
(5,15-diHpETE). Synthesis of 5-HETE, 13HPODE, and 5,15-diHpETE were performed as
previously  described  with  5-LOX  and  AA,  15-LOX-1  and  LA,  15-HPETE  and  5-LOX,
respectively.9,  17,18 The  synthesis  of  5,15-diHETE  was  performed  as  done  for  5,15-
diHpETE, with the exception that trimethylphosphite was added in 2:1 molar excess as
a reductant prior  to the HPLC purification.  5OH,15-HpETE was synthesized from 5-
HETE as follows. 60μM of 5-HETE was reacted in 1 L of 100mM NaBorate, pH 9.2 and 4
mg of lipoxygenase from soybean (Sigma). This reaction was monitored at 254 nm to
completion, quenched with 1% (v/v) glacial acetic acid, extracted with 1 L of DCM, and
evaporated to  dryness.  The 5OH,15-HpETE  was  then purified  isocratically  via  high
performance liquid chromatography (HPLC) on a Higgins Haisil Semi-preparative (5μm,
250mm x 10mm) C18 column with 45:55 of 99.9% acetonitrile, 0.1% acetic acid and
899.9% water, 0.1% acetic acid. Purity was assessed via liquid chromatography-mass
spectrometry to be greater than 90%.  
Expression and Purification of 15-LOX-1, 12-LOX, and 5-LOX.  Overexpression
and  purification  of  wild-type  human  reticulocyte  15-lipoxygenase-1  (15-LOX-1),
platelet  12-lipoxygenase  (12-LOX),  and  5-lipoxygenase  (5-LOX)  were  performed  as
previously described.17, 19, 20 The purity of 15-LOX-1 and 12-LOX were assessed by SDS
gel  to  be  greater  than  85%,  and  metal  content  was  assessed  on  a  Finnigan
inductively-coupled  plasma-mass  spectrometer  (ICP-MS),  via  comparison  with  iron
standard solution. Cobalt-EDTA was used as an internal standard. 5-LOX was isolated
as an impure ammonium sulfate precipitant from E. coli expression due to its dramatic
loss of activity upon isolation.
Product  Analysis  of  LOX  isozyme  reactions  with  5,15-diHpETE,  5-OH,15-
HpETE, and 5,15-diHETE. 15-LOX-1 (120 nM), 12-LOX (250 nM), or 5-LOX (25mg of
ammonium sulfate precipitated protein) was reacted in 12 mL of 25 mM HEPES, pH
7.5, at ambient temperature, with 10 μM of oxylipin (5,15-diHpETE, 5OH,15-HpETE, or
5,15-diHETE) for one hour and quenched with 0.5% glacial acetic acid and 5 μM of 7-
hydroxy-docosahexaenoic  acid  as  an  extraction  standard.  3  μM of  13-HPODE  was
added  to  the  reactions  with  5,15-diHETE  to  activate  iron  as  described  in.21 Each
quenched reactions was extracted with 12 mL of DCM, resuspended in 1 mL methanol
and split 2:1, with the 30% portion being reduced with trimethylphosphite, while the
other 60% was left unreduced. The samples were then evaporated under a stream of
N2 to dryness, reconstituted in 50  μL of methanol, and further diluted with 50  μL of
0.1% formic  acid in  water  prior  to UPLC-MS/MS analysis.  Control  reactions  without
enzymes were also conducted and used for background subtraction, ensuring oxylipin
degradation products were removed from analysis. Chromatographic separation was
9performed on a Dionex UltiMate 3000 UHPLC with a C18 column (Phenomenex Kinetex,
1.7 m, 150mm x 2.1mm). The autosampler was held at 4o C and injection volume was
90 uL. Mobile phase A consisted of water with 0.1% (v/v) formic acid and mobile phase
B was acetonitrile  with  0.1% formic  acid.  Flow rate was 0.400 mL/min.  The initial
condition (30% B) was maintained for 2.3 minutes. Mobile phase B was then ramped
to 65% over 28.7 minutes, held at 65% for 1 minute, ramped to 100% over 0.1 min,
held at 100% for 7 minutes, and finally returned to 30% to equilibrate for 7 minutes.
The chromatography system was coupled to a Dionex Ultimate-3000 DAD and Velos
Pro linear ion trap (Thermo Scientific) for UV and mass spectrum analysis. Analytes
were ionized via heated electrospray ionization with -4.0 kV spray voltage, 60, 10, and
0 arbitrary units for sheath, auxiliary and sweep gas, respectively. The RF amplitude of
the S-Lens was 49%, and the probe and capillary temperatures were 50o C and 380o C,
respectively.  All  analyses  were  performed  in  negative  ionization  mode  at  Normal
resolution  setting.  MS2 was  performed  at  35%  normalized  collision  energy  in  a
targeted manner with a mass list containing the following m/z ratios  + 0.1:  319.2,
335.2, 343.2, 351.2, 367.2, 383.2, and 399.2. Products were identified by matching
retention times, UV spectra and fragmentation patterns to known standards. Or in the
cases  where  MS  standards  were  not  available,  structures  were  deduced  from
comparison to known and theoretical fragments.
Steady State Kinetics of 5-LOX, 12-LOX and 15-LOX-1 with 5,15-diHpETE, 12-
LOX with 5,15-diHETE. 15-LOX-1 and 5-LOX reactions were performed, at ambient
temperature, in a 1 cm2 quartz cuvette containing 2 mL of 25 mM HEPES, pH 7.5 with
substrate (AA, 15HpETE, or 5,15-diHpETE). 12-LOX reactions were also performed in a
1 cm2  quartz  cuvette  containing 2  mL of  25 mM HEPES with  substrate  (AA,  5,15-
diHpETE,  or 5,15-diHETE),  and the pH was 8.0.  Additionally,  12-LOX reactions with
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5,15-diHETE contained 3 μM 13-HPODE and 5-LOX reactions contained 200 M ATP. AA
concentrations were varied from 0-29 μM, 15-HpETE concentrations were varied from
0-80  M, 5,15-diHpETE concentrations  were varied from 0-45  μM, and 5,15-diHETE
concentrations were varied from 0-130 μM. 5-LOX reactions were compared using 10
M substrate for AA, 15-HpETE, and 5,15-diHpETE with product formation per time
analyzed  on  UV-Vis  as  well  as  LC/MS.  Concentration  of  AA  was  determined  by
measuring the amount of 15-HpETE produced from complete reaction with soybean
lipoxygenase-1  (sLO-1).  Concentrations  of  5,15-diHpETE  and  5,15-diHETE  were
determined by absorbance at 247 nm. Reactions were initiated by the addition 15-
LOX-1  (120  nM)  or  12-LOX  (250  nM)  or  5-LOX  (approx.  200  nM  of  crude  AS
preparation)  and  were  monitored  on  a  Perkin-Elmer  Lambda  45  UV/VIS
spectrophotometer. Product formation was determined by the change in absorbance
at 234 nm for  15-HpETE/5HpETE (ε234nm = 25,000 M-1 cm-1),  5,15-diHpETE (ε254nm =
21,90000 M-1 cm-1),9 and 302 nm for lipoxins (ε234nm = 50,000 M-1 cm-1). KaleidaGraph
(Synergy)  was used to fit  initial  rates (at less than 20% turnover),  as well  as the
second order derivatives (kcat/KM) to the Michaelis-Menten equation for the calculation
of kinetic parameters.
5,15-diHpETE  and  LXB4 titration  into  human  platelets.  The  University  of
Michigan Institutional Review Board approved all research involving human volunteers.
Washed human platelets (250 µL at 3.0 x108 platelets/mL) were dispensed into glass
cuvettes and incubated with 0-10 µM of either LXB4 or 5,15-diHpETE for 10 minutes at
37°C.  Oxylipin-treated platelets  were  then stimulated with  0.25  µg/mL of  collagen
(Chrono-log),  stirring  at  1100  rpm  and  37°C,  in  a  Chrono-log  Model  700D  lumi-
aggregometer and platelet aggregation was recorded for six minutes.
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In  order  to  determine  the  biosynthetic  products  of  5,15-diHpETE  ex  vivo,
platelets were isolated from human whole blood via serial centrifugation and adjusted
to 3.0 x 108 platelets/mL in Tyrode’s buffer (10 mM HEPES, 12 mM NaHCO3, 127 mM
NaCl, 5 mM KCl, 0.5 mM NaH2PO4,  1 mM MgCl2,  and 5 mM glucose), as previously
published.22 One ml of platelets was incubated with varying concentrations of 5,15-
diHpETE (0-20 µM) or vehicle (DMSO) for 10 minutes at 37 C, and then the platelets
were  pelleted  by  centrifugation  at  1000  x  g  for  1  minute.  The  supernatant  was
transferred to a fresh tube and snap frozen. Oxylipins were extracted and analyzed via
UPLC-MS/MS  as  described  previously,9 with  the  following  exceptions.  The  m/z
transitions  for  5,15-diHETE,  LTB4-d4,  RvD2-d5,  and  LipoxinB4 were  335.2115,
339.2197, 380.5141, and 351.2221, respectively. 
Results and Discussion
Lipoxin synthesis  from 5,15-diHpETE, 5-OH,15-HpETE, and 5,15-diHETE.  To
study  the  conversion  of  5,15-diHpETE  to  LX  through  product  identification,  5,15-
diHpETE was reacted with human 5-LOX, 12-LOX, and 15-LOX-1. For the reaction of 5-
LOX  with  5,15-diHpETE,  no  activity  was  detected  at  302  nm  (the  absorbance  of
conjugated lipoxins) and LXA4 and LXB4 were both undetected via LC-MS.  This data
indicates  that  5,15-diHpETE  is  a  poor  substrate  for  5-LOX  in  vitro.  In  order  to
determine the relative turnover of 5,15-diHpETE with 5-LOX, the rate of AA, 15-HpETE
and  5,15-diHpETE  were  compared  under  the  same  reaction  conditions.  5-LOX
converted AA to 5-HpETE at 5 ng/sec and 15-HpETE to 5,15-diHpETE at 0.5 ng/sec, but
there was no conversion of 5,15-diHpETE to LXA4 observed (the detection limit of the
experiment is 0.0003 ng/sec). This data indicates that the oxidation reaction of 5-LOX
with 5,15-diHpETE is more than 1700-fold slower than that with 15-HpETE. This was
unexpected  because  5-LOX  abstracts  the  C10  hydrogen  atom  from  5-HpETE  to
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generate leukotriene A4, (LTA4) which is the same hydrogen atom presented by 5,15-
diHpETE. In addition, the hydrogen atom on C10 for 5,15-diHpETE is more reactive
than that of 15-HpETE, due to conjugation,9 making this lack of reactivity even more
noteworthy. However, 5-LOX is able to convert 15-HpETE into  LXA4 at a rate of 0.5
ng/sec. This difference in reactivity of 5,15-diHpETE versus 15-HpETE is most likely
due to a difference in the rate of substrate capture, as defined by Northrop et al.23, 24
Previously, we have shown that the kcat for generating LTA4 is the same when starting
with arachidonic acid (AA) or 5-HpETE. However, the  kcat/KM is 10-fold slower for 5-
HpETE  than  AA,  due  to  a  slow  binding  step.17 We  propose  that  5-LOX’s  lack  of
reactivity with 5,15-diHpETE is due to an even slower binding step for 5,15-diHpETE
relative to 5-HpETE, limiting reactivity completely. We therefore propose that 5-LOX
produces LXA4 from 15-HpETE by generating 5,15-diHpETE in situ and subsequently
generates  LXA4 without  releasing  the  5,15-diHpETE  intermediate,  similar  to  the
mechanism for LTA4 synthesis.
In contrast, both 12-LOX and 15-LOX-1 reacted with 5,15-diHpETE, manifesting
observable  rates  at  302  nm,  which  is  consistent  with  LXs  being  formed.   LC-MS
analysis of the reduced products confirmed that both 12-LOX and 15-LOX-1 made LXB4
(RT = 8.8 min), but not LXA4 (Figure 2, dashed traces). We also observe LXB4 isoforms,
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with the all-trans-LXB4 (RT = 8.1 min), 14S-LXB4-epimer (RT = 8.9 min), and the 14S-
all-trans-LXB4-epimer (RT = 8.2 min). These products are synthesized by the opening
of the epoxide via dehydration, as previously observed with purified rabbit 15-LOX-1
and 15-HpETE as  the substrate.12 However,  some of  these products  could  also  be
formed by the competing reaction, oxygenation. In order to differentiate these two
reaction mechanisms, the reaction products were analyzed without reductant added
during  product  extraction  (Figure  2,  solid  traces).  Both  dehydration  (i.e.  epoxide
formation) and oxygenation require abstraction at C10, with migration of the radical to
C14. Dehydration occurs upon reaction of the radical with the hydroperoxide in an
anti-periplanar orientation, while oxygenation occurs with antarafacial attack of the
radical  by  molecular  oxygen.  Both  reactions  require  the  active  site  ferrous-water
species  to  reduce  the  radical  intermediate  and form the final  product.  Comparing
reduced and un-reduced products  can contribute to differentiating the two sets of
products,  hydroperoxides and alcohols,  produced by oxygenation  and dehydration,
respectively.  Analysis  of  the  data  clearly  demonstrates  that  hydroperoxides  are
present, due to the fact that many of the peaks migrated to shorter retention times
upon reduction. Specifically, the tri-hydroperoxy species (5,14,15-triHpETE, RT = 13.6
min, Figure 2) is  observed, which could only be formed via oxygenation at C14. It
should be noted that while we observe the parent mass of 5,14,15-triHpETE (399 m/z,
hydrogen loss in the negative mode), we also observe the neutral loss of water from
5,14,15-triHpETE (Supplemental  S2),  resulting  in  the most  intense ion  for  5,14,15-
triHpETE at 381 m/z. Additionally,  because there are three hydroperoxide moieties,
multiple  peaks  that  correspond  to  the  loss  of  up  to  three  waters  upon  ionization
(Supplemental S1 & S2) are observed. The additional hydroperoxide peaks correspond
to both oxygenation products, which have lost an oxygen, most likely due to reduction
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during the long reaction time in buffer. These products include: 5-OOH,14-OOH,15-
OOH-triHpETE (RT = 13.7 min), 5-OOH,14-OH,15-OOH-triHETE, 5-OH,14-OOH,15-OOH-
triHETE,  5-OH,14-OH,15-OOH-triHETE,  5-OOH,14-OOH,15-OH-triHETE,  and  5-OH,14-
OOH,15-OH-triHETE.  These  products  exhibit  multiple  peaks,  which  most  likely
correspond not only to the hydroperoxide position in these molecules, but also to the
all-trans,  S-epimers,  and  other  isomers  resulting  from  the  non-enzymatic  epoxide
opening at C14 and C15. The non-enzymatic epoxide opening is also supported by
comparing the ratio of the sum of all-trans-LXB4, 14S-LXB4 and 14S-all-trans-LXB4 to
LXB4 in the reduced samples of 5,15-diHpETE (LxB4 isomers and epimers/LxB4 = 0.91
+ 0.2) and 5,15-diHETE (LxB4 isomers and epimers = 0.19 + 0.02) as substrates with
12-LOX. The dehydration and oxygenation peaks have been quantified, demonstrating
no  preference  for  dehydration  over  oxygenation,  with  12-LOX  having  a
dehydration/oxygenation ratio of 1.3 + 0.2 and 15-LOX-1 having a ratio of 1.2 + 0.2
(Figure 2,  supplemental  S2). Since only LXB4 is  produced by 12-LOX and 15-LOX-1
from 5,15-diHpETE, with it being generated either through oxygenation or dehydration
(i.e. via the epoxide), the data indicates similar LX reactivities for both LOX isozymes.
It should be noted that due to the reactive nature of these di- and tri-hydroperoxides,
the data was scanned for Hock rearrangement decomposition, however, no evidence
was observed for these products.25 
To eliminate the possibility of epoxide generation, 12-LOX and 15-LOX-1 were
reacted with 5,15-diHETE, the reduced form of 5,15-diHpETE, which is incapable of
forming epoxides. 12-LOX reacted with 5,15-diHETE producing LxB4 and its isoforms,
but  13-HPODE  was  required.  13-HPODE  is  a  known  oxidant  of  lipoxygenase  that
reduces lag times and expands the substrate range of lipoxygenases by activating the
LOX  isozyme  when  the  endogenous  hydroperoxide  product  cannot  oxidize  the
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intermediate ferrous ion.18, 26 For this particular reaction, the conversion of 5,15-diHETE
to LXB4 implies that 12-LOX oxygenates at C14 because the 14,15-epoxide cannot be
formed from the alcohol. The requirement of 13-HpODE is because the ferrous-water
intermediate  cannot  efficiently  reduce  the  hydroperoxide  radical  at  C14,  thus
releasing the radical intermediate and generating the inactive ferrous-water species.
The ferrous-water intermediate is subsequently oxidized by 13-HpODE, generating the
active form of 12-LOX. This conclusion is supported by the comparison of the reduced
and un-reduced products (Figure 3). The un-reduced reaction manifests a large peak
(RT = 9.8 min),  which elutes after LxB4 (RT = 8.8  min).  This  peak has an MS/MS
fragmentation  pattern  of  a  C14  hydroperoxy  moiety  (supplemental  S3),  which
becomes LxB4  upon reduction, as seen by its change in retention time and its MS/MS
fragmentation  (supplemental  S3)  and confirms an oxygenation  reaction  on C14.  It
should be noted that we observe a large reduction in the number of isoforms of LxB4,
as compared to the reaction with 5,15-diHpETE as the substrate. This is appropriate
given that this is a region- and stereo-specific oxygenation reaction and no epoxide
was  formed  that  could  undergo  non-enzymatic  hydrolysis  to  generate  the  LxB4
isoforms.
Interestingly,  15-LOX-1  cannot  perform  an  oxygenation  reaction  with  5,15-
diHETE, even with 13-HPODE present, indicating that 15-LOX-1 cannot oxygenate at
C14  with  5,15-diHETE  as  the  substrate.  This  is  unexpected  since  15-LOX-1  can
oxygenate 5,15-diHpETE. Therefore, the hydroxides at C5 and C15 appear to change
substrate binding so that either the hydrogen atom abstraction at C10 is prohibited or
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the  oxidation  of  the  active  site  ferrous-water  intermediate  to  the  active  ferric-
hydroxide  moiety  by  the  hydroperoxyl  radical  is  prohibited.  This  hypothesis  is
supported by the fact that hydroperoxyl moieties in these eicosanoids behave more
hydrophobically than hydroxyl moieties, as evident by their longer retention on a C18
column (Supplemental S1). In addition, 15-LOX-1 will not oxygenate 15-HETE either,
but it will oxygenate 15-HpETE, indicating a difference in reactivity with the reduced
oxylipin. 
It should be reiterated that 15-LOX-1 and 12-LOX do not make LXA4 from 5,15-
diHpETE, however, they do make LXB4. This is an interesting observation considering
that the radical intermediate of 5,15-diHpETE can potentially form either the 5,6- or
14,15-epoxide. However, the active sites of both 12-LOX and 15-LOX-1 preferentially
generate only the 14,15-epoxide. This restricted reactivity could be related to the fact
that the oxygen tunnel for both 15-LOX-1 and 12-LOX is located near C14, as observed
by the C14 oxygenation products.27, 28 Therefore, the opening to the oxygen tunnel in
the active site could provide a dual function. Primarily to oxygenate 5,15-diHpETE but
also to provide the space for the 14,15-epoxide to form, thus giving the oxygen tunnel
an added functionality. 
Steady-state kinetics of 15-LOX-1 and 12-LOX with 5,15-diHpETE and
12-LOX with 5,15-diHETE. Considering that hydrogen atom abstraction is typically
rate-limiting in lipoxygenase reactions,29-31 the steady-state kinetics of 15-LOX-1 and
12-LOX with 5,15-diHpETE revealed an interesting difference between their relative
rates. When reacted with AA, 12-LOX abstracts the hydrogen atom at C10, generating
more than 95% 12-HpETE.19 On the other hand, 15-LOX-1 abstracts the hydrogen atom
at C10 only ≈10% of the time, with C13 being the major target.32-34 We confirmed this
result  by  observing  approximately  10% of  12-HpETE  and  90% of  15-HpETE  being
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generated from AA reacted with 15-LOX-1. Therefore, 12-LOX has a 78-fold larger kcat/
KM than 15-LOX-1 for abstracting the hydrogen atom from C10 of AA and generating
12-HpETE, 18  μM-1s-1  and 0.23  μM-1s-1, respectively (Table 1). It should be noted that
these 15-LOX-1 kinetic values for C10 abstraction are estimated from the total rate
observed for 15-LOX-1 and its product percentages. This indicates that 12-LOX is more
efficient in both product release (kcat) and substrate capture (kcat/KM) than 15-LOX-1 in
abstracting a hydrogen atom from C10 on AA (13-fold for kcat and 78-fold for kcat/KM).
However, despite the preference of 12-LOX for abstracting at C10 on AA, 15-LOX-1 has
both a better product release rate (kcat) and substrate capture rate (kcat/KM) than 12-
LOX, for abstracting the C10 hydrogen atom from 5,15-diHpETE (Table 1). For kcat, the
12-LOX rate for C10 abstraction from 5,15-diHpETE is 106-fold less than that of AA (kcat
= 0.17 s-1), while the 15-LOX-1 rate is 3.3-fold greater than that of C10 abstraction
from AA (kcat = 4.6 s-1). For  kcat/KM,  the 12-LOX rate for C10 abstraction from 5,15-
diHpETE is 1600-fold less than that of AA (kcat/KM = 0.011 μM-1s-1), while the kcat/KM for
15-LOX-1 is  the  same as  that  of  C10 abstraction  from AA (kcat/KM =  0.21  μM-1s-1).
Effectively, there is no loss of activity for 15-LOX-1 abstracting the hydrogen atom
from C10 of 5,15-diHpETE relative to AA, but 12-LOX has a large loss of activity with
5,15-diHpETE relative to AA, as seen by a significant decrease in kcat and kcat/KM (Table
1). This data indicates that the hydroperoxy moieties on C5 and C15 of 5,15-diHpETE,
disrupt its positioning in the 12-LOX active site for C10 abstraction significantly, while
not affecting 15-LOX-1 appreciably. It should be noted that for both 12-LOX and 15-
LOX-1, only 10% of the total 5,15-diHpETE in the reaction is converted to LXB4 and
addition of 12-LOX, 15-LOX-1 or 5,15-diHpETE at 10% conversion did not improve the
turnover percentage. This implies that there is some form of suicide product inhibition,
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which is a common observation in LOX reactions, due to the reactive nature of the
radical intermediates, and has previously been observed with 12-LOX and LTA4.35, 36
As noted above, LX formation from the reduced intermediate, 5,15-diHETE, is
only observed with 12-LOX in the presence of 13-HPODE, and no rate was observed for
15-LOX-1.  However,  the  rate  of  12-LOX  with  5,15-diHETE  is  extremely  slow,
manifesting a  kcat/KM that is  10-fold less than that seen for 5,15-diHpETE (kcat/KM =
0.0015 μM-1s-1). Since the kcat of 12-LOX with 5,15-diHETE is essentially the same as its
kcat for 5,15-diHpETE, this lower rate of substrate capture (kcat/KM) is manifested in a
10-fold increase in  KM, (113  + 19  μM). As discussed above, 12-LOX only oxygenates
5,15-diHETE but it oxygenates and dehydrates 5,15-diHpETE. Since the  kcat for both
Figure 4: 5,15-diHpETE, but not LXB4, inhibits collagen-mediated platelet aggregation. Isolated human 
platelets were treated with increasing concentrations of either LXB4 or 5,15-diHpETE for ten minutes and then 
stimulated with collagen (0.25 µg/mL). A) Representative tracings of 5,15-diHpETE or LXB4 treated platelets 
stimulated with collagen. B) Data represents mean ± S.E.M. Statistical analysis was performed comparing oxylipin
concentration to vehicle control using one-way ANOVA with Dunnett’s multiple comparison test. *P<0.05, 
**P<0.01, ***P<0.001.
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5,15-diHETE and 5,15-diHpETE are similar, it indicates that the rate of product release
for both oxygenation and dehydration are also similar. This implies that the reaction
steps after the irreversible hydrogen abstraction step, such as the reduction of the
radical intermediate for oxygenation or dehydration by the ferrous-water moiety, are
either not rate-limiting or comparable in rate for the two reactions. It is also observed
that the rate of substrate capture (kcat/KM)23 for 12-LOX is decreased by a factor of 10
for 5,15-HETE relative to 5,15-HpETE, indicating that there is a rate difference in a
reaction  step  prior  to  the  irreversible  hydrogen  atom  abstraction  step,  such  as
substrate binding. As mentioned above, this could be due to its smaller size or the
more polar  hydroxyl  moiety relative to the hydroperoxide,  as seen by its  RP-HPLC
retention time.
5,15-diHpETE and LXB4 titration into human platelets. To determine whether or
not 5,15-diHpETE inhibits platelet activation, platelets from 11 separate donors were
treated with varying concentrations of  5,15-diHpETE (0.5-20 μM) or vehicle control
(DMSO)  prior  to  stimulation  with  collagen,  a  GPVI  and  α2β1 agonist.  Compared  to
vehicle control,  5,15-diHpETE inhibited platelet aggregation in response to collagen
(0.25 µg/mL) stimulation with an IC50 of 1.3 μM (Figure 4).  Furthermore, over 90%
Figure 5: Platelets produce LxB4 from 5,15-diHPETE. The amount of LxB4 produced by platelets treated
with 5, 10 or 20 M of 5,15-diHPETE are plotted in this histogram. The standard deviation of each value is 
represented by error bars.
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reduction in collagen-mediated platelet aggregation was observed in platelets treated
with a concentration greater than 10 μM of 5,15-diHpETE. The antiplatelet effects of
LXB4 were  also  investigated;  however,  in  contrast  to  5,15-diHpETE,  LXB4 did  not
significantly inhibit collagen-mediated platelet activation at the concentrations tested. 
With respect to the biosynthetic pathway, human platelets were treated with
5,15-diHpETE and shown to produce LXB4 (Figure 5), but they did not produce LXA4.
This is consistent with the in vitro results, where purified 12-LOX only makes LXB4.
However, the amount of LXB4  that we observe from 5,15-diHpETE treated platelets is
very small compared to the unreacted 5,15-diHpETE (less than 1.2 %), indicating that
this is not an efficient pathway for the generation of LXB4. In addition, since LXB4 does
not have a strong antiplatelet effect, it is reasonable to conclude that 5,15-diHpETE,
and  not  its  downstream product,  LXA4,  is  the  active  oxylipin  species  that  affects
platelet biology in our experiments.
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In  summary,  the  reaction  of  5,15-diHpETE  with  various  human lipoxygenase
isozymes  was  investigated  to  determine  the  relative  rates  of  producing  LXs.
Previously,  it  was  established  that  15-LOX-2  did  not  react  with  5,15-diHpETE,
consistent with its enhanced substrate selectivity relative to the other LOX isozymes.9
15-LOX-2 abstracts a hydrogen atom from C13 of AA, but does not abstract from C10,
the  only  available  methylene  carbon  of  5,15-diHpETE.  In  the  current  work,  it  was
determined that 5-LOX does not react with 5,15-diHpETE either. However, 5-LOX can
produce LXA4 if 15-HpETE is the substrate (Figure 6), indicating that substrate binding
is  impaired  when  the  hydroperoxide  is  on  both  C5  and  C15,  consistent  with  our
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previous work with 5-LOX where oxygenation of the oxylipin affects substrate binding
significantly.17 In contrast, both 12-LOX and 15-LOX-1 react with 5,15-diHpETE (Figure
6), albeit at slow rates relative to AA. Surprisingly, 15-LOX-1 has a 27-fold greater kcat
and a 20-fold greater  kcat/KM than 12-LOX. This result is unusual because C10 is the
preferred location for hydrogen abstraction for 12-LOX, so it appears that the active
site of 12-LOX is less tolerant of oxygenated fatty acids than 15-LOX-1, which lowers
its catalytic rates, as already seen for 5-LOX.17 The low in vitro catalytic rate for 12-
LOX with 5,15-diHpETE is corroborated by the fact that when 5,15-diHpETE is added to
platelets, LXB4 production is extremely low (1.2 + 0.2 % total conversion), consistent
with  the  poor  in  vitro LXB4 production  rate.  This  result  is  in  contrast  to  the
conventional  wisdom  that  assumes  12-LOX  is  the  biosynthetic  enzyme  for  LXs
production from 5,15-diHpETE, due to its preference for abstracting a hydrogen atom
from C10.8 Nevertheless, LXs are highly active molecules so low production levels in
platelets could still have large effects on the cellular response, resulting in 12-LOX still
being  a  potentially  biosynthetically  relevant  LOX  isozyme  for  making  LXs.  For
comparison, Serhan and coworkers determined that human 12-LOX reacted with LTA4,
producing both LXA4 and LXB4, with a Vmax of 24.5 nmol/min/mg (or a kcat of 0.031 sec-1)
and a  Vmax/Km of 3.1 nmol/min/mg/uM (or a  kcat/KM of 0.004 sec-1uM-1).35 These values
are markedly slower than the current observed rates of 15-LOX-1 with 5,15-diHpETE
(150-fold slower for kcat and 50-fold slower for kcat/KM), suggesting that 15-LOX-1 may
be a more predominant source of LXs than 12-LOX, depending on the cells involved.
Another interesting difference between 5,15-diHpETE and LTA4 as LOX substrates is
that with LTA4, both LXA4 and LXB4 are made, but with 5,15-diHpETE as the substrate,
only LXB4 is made. Clearly, the mechanisms of LX production are distinct, which could
help in the future identification of the source of LX biosynthesis. For example, if 5,15-
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diHpETE  is  the  substrate,  LXB4 is  the  primary  product  of  12-LOX  and  15-LOX-1
catalysis,  whereas LXA4 is the primary product with 5-LOX. However, if  LTA4 is  the
substrate, then 12-LOX generates both LXA4 and LXB4. Therefore, it appears that cells
have multiple pathways for making LXs, depending on the available LOX isozyme and
the  available  substrate,  5,15-diHpETE  or  LTA4.  We  are  currently  investigating  the
molecular  mechanism of  these reactions with active site  mutants  in  order to gain
better insights into the differences between these distinct LX biosynthetic pathways.
Supplemental information.  The supplemental  figures that are referenced in this
article (S1, S2, S3 and S4) along with their corresponding legends are available online.
These materials are supplied free of charge at http://pubs.acs.org. 
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